Fox Chase Cancer Center News

A study presented by researchers at Fox Chase Cancer Center finds that the type of therapy a patient receives before surgery for pancreatic ductal adenocarcinoma has more of an impact on postoperative outcomes and survival than the duration of treatment.

Jaylin Staunton, MS, RD, LDN, CNSC, Lead Clinical Dietitian Specialist at Fox Chase Cancer Center, was awarded the Recognized Young Dietitian of the Year Award by the Pennsylvania Academy of Nutrition and Dietetics.

Alexander Kutikov, MD, FACS, Chair of the Department of Urology at Fox Chase Cancer Center, recently co-edited and contributed to a new edition of Urologic Clinics of North America Focused on Adrenal Tumor Diagnosis and Treatment.

Adria Hasan, PhD, a postdoctoral associate at Fox Chase Cancer Center, was recently honored with the American Association for Cancer Research’s (AACR) John Kincade Scholarship Fund Scholar-in-Training Award.

Parastomal hernia is a common complication among patients who undergo bladder removal and ileal conduit urinary diversion. Now, a new study presented by Fox Chase Cancer Center clinicians at the American Urological Association’s (AUA) Annual Meeting supports the use of partially absorbable synthetic, non-biologic parastomal mesh to significantly reduce this risk in real-world practice.

Fox Chase Cancer Center and Fox Chase – Temple Urologic Institute physicians participated in the presentation and discussion of a number of research projects at the American Urological Association meeting, which was held April 26-29 in Las Vegas.

Fox Chase Cancer Center’s Jonathan Chernoff, MD, PhD, Cancer Center Director, was recently elected to one of the nation’s most prestigious medical organizations, the Association of American Physicians (AAP).

Physicians at Fox Chase Cancer Center have begun accepting patients for a new clinical trial looking at the effectiveness of a hepatic artery infusion (HAI) pump along with standard chemotherapy. Fox Chase is the only local hospital offering this trial, which is designed for patients with colorectal cancer that has spread to the liver and cannot be treated with surgery.